Skip to content

The Biological Specificity of Acupoints Between Major Depressive Disorder Patients and Healthy Controls

The Biological Specificity of Acupoints Between Major Depressive Disorder Patients and Healthy Controls: A Prospective, Assessor-blinded, Comparative Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06114342
Enrollment
184
Registered
2023-11-02
Start date
2022-01-10
Completion date
2022-09-30
Last updated
2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

Major Depressive Disorder, Acupoint, Biological specificity

Brief summary

Evidence-based medicine suggests that acupuncture can improve major depressive disorder (MDD). However, the prevalent reliance on experiential acupoint selection lacks scientific underpinning. The investigators conducted a comparative study involving MDD patients and healthy subjects, employing modern techniques to discern biological specificity in MDD-related acupoints. Additionally, the investigators investigated potential correlations between acupoint biological specificity and MDD severity.

Detailed description

A final total of 134 eligible subjects were included. Among them, 50 healthy subjects were assigned to the healthy control (HC) group and 84 MDD participants were assigned to the MDD group.

Interventions

None listed

Sponsors

Zhejiang Provincial Tongde Hospital
CollaboratorOTHER
First People's Hospital of Hangzhou
CollaboratorOTHER
Xiaomei Shao
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion criteria for the healthy control participants: * provided a recent depression screening report, and be free of any cardiovascular, respiratory, digestive, urinary, hematological, endocrine, or neurological disease; * 18 ≤ age ≤60 years, male or female; * had clear consciousness and could communicate with others normally; - understand the full study protocol and have high adherence; * signed the written informed consent. Inclusion criteria for the MDD participants: * consistent with the diagnosis of MDD in the International Classification of Diseases 10th Edition (ICD-10); * 18 ≤ age ≤ 60, male or female; * had clear consciousness and could communicate with others normally; * understand the full study protocol and have high adherence; * signed the written informed consent.

Exclusion criteria

* The

Design outcomes

Primary

MeasureTime frameDescription
TemperatureBaselineTemperature of acupoints was measured by infrared thermography (IRT). IRT was not be performed on female subjects during their menstrual and ovulatory periods.
Pressure pain thresholdBaselinePressure pain threshold was measured by pressure pain threshold gauge (PTG).

Secondary

MeasureTime frameDescription
The Hamilton Depression Scale-17 (HAMD-17) ScoresBaselineThe HAMD scale is the most commonly used in the clinical assessment of depression, including 17 items. The higher the score, the more severe the depression. 0-6 means no depressive symptoms, 7-16 means mild depression, 17-24 was divided into moderate depression, and more than 25 was divided into severe depression.
The Patient Health Questionaire-9 Items (PHQ -9)BaselineThe PHQ-9 scale has a total of 9 questions, each with a score of 0-3 (none: 0; a few days: 1; more than half of the time: 2; almost every day: 3), with a total score of 0-27.
The Self-Rating Depression Scale (SDS) ScoresBaselineThe standard score is the total of all scores multiplied by 1.25 to the nearest whole number on this scale, which has 20 questions. A standard score below 50 is normal; 53-62 is mild depression; 63-72 is moderate depression; 72 or more is severe depression.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026